Purdue Pharma on Wednesday filed a new bankruptcy reorganization plan to resolve mass lawsuits alleging that the OxyContin maker and its Sackler family owners contributed to the opioid crisis.

Purdue Pharma has filed a new bankruptcy plan as part of a $7.4 billion settlement to resolve thousands of lawsuits over the company’s alleged role in the opioid crisis, months after the Supreme ...

Purdue Pharma on Wednesday filed a new Chapter 11 reorganization plan with the U.S. Bankruptcy Court for the Southern District of New York to settle opioid-related claims involving the company for ...

Previously at the epicenter of the U.S. opioid crisis, Purdue Pharma is looking to reenter the public lexicon as a new public benefit company. After a prior bankruptcy settlement was nixed by the ...

Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid settlement of at least $7.4 billion after a setback in the U.S. Supreme Court last year.

Purdue Pharma LP has filed a new Chapter 11 plan with the US Bankruptcy Court for the Southern District of New York, pledging it will give creditors including US states and other parties more than ...

About Purdue Pharma L.P. Purdue Pharma and its subsidiaries develop, manufacture and market medications to meet the evolving needs of healthcare professionals, patients, and caregivers.

Purdue Pharma asked a bankruptcy judge late Tuesday to consider the latest version of its plan to settle thousands of lawsuits over the toll of the powerful prescription painkiller OxyContin ...

Prior to 60 Minutes' March 9, 2025 broadcast, which featured correspondent Cecilia Vega's report on the Purdue Pharma bankruptcy case, we reached out to Purdue Pharma for comment on our story ...

Hampton was appointed by the Justice Department in 2019 to represent the financial interests of victims in the Purdue Pharma bankruptcy case. For two years, he served on a committee of creditors.

NASHVILLE, Tenn. (WKRN) — A bipartisan coalition of states, including Tennessee, will receive $7.4 billion from Purdue Pharma, Inc. and members of the Sackler family for their “instrumental ...